Studies by Schmittnaegel et al.49 and Elizabeth et al.50 provide evidence that antiangiogenic drugs specifically improve anti-PD-1/PD-L1 therapy when promoting an immunostimulatory tumor microenvironment and tumor vascular normalization in various tumor models. Here, CD274 is linked to neoplasm.